[{"id":"876c2e70-4925-4835-9b88-46d9ace36858","acronym":"ComboMATCH Treatment Trial","url":"https://clinicaltrials.gov/study/NCT05564403","created_at":"2022-11-26T21:57:48.468Z","updated_at":"2025-02-25T13:41:17.315Z","phase":"Phase 2","brief_title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05564403 - ComboMATCH Treatment Trial","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/09/2024","start_date":" 02/09/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 01/21/2026","study_completion_date":" 01/21/2026","last_update_posted":"2025-02-21"},{"id":"6e8c9c85-9d26-4c35-8860-c80648e49b52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02188264","created_at":"2021-01-18T10:12:45.005Z","updated_at":"2025-02-25T15:25:18.307Z","phase":"Phase 1","brief_title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02188264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAF1 • MAPK1","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • RAF1 • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/29/2014","start_date":" 08/29/2014","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2025-02-11"},{"id":"0db68b48-63b4-415c-9bee-7380074c53b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05396859","created_at":"2022-05-31T12:54:45.824Z","updated_at":"2024-07-02T16:35:14.538Z","phase":"Phase 1","brief_title":"Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT05396859","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • RUNX1 • MAPK1 • NTRK • MAPK3","pipe":" | ","alterations":" TP53 mutation • NTRK expression","tags":["TP53 • RUNX1 • MAPK1 • NTRK • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-15"},{"id":"a03225ff-24b0-4deb-bd39-a4f4a7489157","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221320","created_at":"2022-02-05T18:29:02.167Z","updated_at":"2024-07-02T16:35:19.608Z","phase":"Phase 2","brief_title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","source_id_and_acronym":"NCT05221320","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3","pipe":" | ","alterations":" MSI-H/dMMR","tags":["KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 12/06/2024","primary_completion_date":" 12/06/2024","study_txt":" Completion: 03/19/2025","study_completion_date":" 03/19/2025","last_update_posted":"2024-02-13"},{"id":"63d174f5-1045-41f8-a030-f399abb4d1dd","acronym":"NCI-2016-00073","url":"https://clinicaltrials.gov/study/NCT02697344","created_at":"2021-01-18T13:10:03.223Z","updated_at":"2024-07-02T16:35:25.022Z","phase":"Phase 1","brief_title":"Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma","source_id_and_acronym":"NCT02697344 - NCI-2016-00073","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • CRBN • MAPK1","pipe":" | ","alterations":" BCL2 expression • CRBN expression","tags":["BCL2 • CRBN • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • CRBN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/14/2016","start_date":" 04/14/2016","primary_txt":" Primary completion: 10/26/2018","primary_completion_date":" 10/26/2018","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2023-12-28"},{"id":"2f6706b3-4373-4123-bd41-4a6388aa2fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566393","created_at":"2021-01-18T21:48:48.647Z","updated_at":"2024-07-02T16:35:39.652Z","phase":"","brief_title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","source_id_and_acronym":"NCT04566393","lead_sponsor":"xCures","biomarkers":" BRAF • NRAS • HRAS • MAPK1","pipe":" | ","alterations":" BRAF mutation • ER mutation • HRAS mutation","tags":["BRAF • NRAS • HRAS • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ER mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-21"},{"id":"478022aa-8fe1-4731-9654-44045727b783","acronym":"","url":"https://clinicaltrials.gov/study/NCT01719380","created_at":"2021-01-17T17:53:34.887Z","updated_at":"2024-07-02T16:36:28.705Z","phase":"Phase 2","brief_title":"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01719380","lead_sponsor":"Pfizer","biomarkers":" EGFR • BRAF • PIK3CA • MET • PTEN • HRAS • MAPK1","pipe":"","alterations":" ","tags":["EGFR • BRAF • PIK3CA • MET • PTEN • HRAS • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Piqray (alpelisib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 11/23/2012","start_date":" 11/23/2012","primary_txt":" Primary completion: 10/31/2015","primary_completion_date":" 10/31/2015","study_txt":" Completion: 02/12/2019","study_completion_date":" 02/12/2019","last_update_posted":"2021-06-23"},{"id":"8d0f86f7-c4c8-468d-be6d-e8ccc24dc6cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070057","created_at":"2024-01-06T23:17:02.166Z","updated_at":"2024-07-02T16:37:26.857Z","phase":"Phase 1","brief_title":"Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer","source_id_and_acronym":"NCT00070057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1 • MAPK3","pipe":"","alterations":" ","tags":["MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 04/01/2003","start_date":" 04/01/2003","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2016-12-29"},{"id":"94be0e95-96d0-4df2-b9a7-e2ea9489ceb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01553851","created_at":"2024-01-06T23:17:03.243Z","updated_at":"2024-07-02T16:37:26.880Z","phase":"Phase 2","brief_title":"GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer","source_id_and_acronym":"NCT01553851","lead_sponsor":"Washington University School of Medicine","biomarkers":" MAPK1 • MAPK3","pipe":"","alterations":" ","tags":["MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2016-12-26"}]